- Mark Zylka, PhD
-
Research
Lab Members
Images
Publications
Biosketch [pdf]
Rotations
Associate ProfessorEducation:
PhD, Harvard University, 1999Molecules and Mechanisms for Pain
Angelman Syndrome Therapies
- Contact
-
5109D Neuroscience Research Building
Campus Box 7545Office (919) 966-2540 • Lab (919) 966-2541
- Center and Program Memberships
Summer undergraduate researchers join the department
June 2012 - Undergraduate students join department labs for summer research experience
Pain relief with PAP injections may last 100 times longer than a traditional acupuncture treatment
April 2012 - Zylka lab publication in the journal "Molecular Pain" outlines the pain relief potential of PAP injections.
Potential treatment strategy for Angelman syndrome identified by Philpot, Zylka and Roth
December 2011 - Collaborators Ben Philpot, Mark Zylka and Bryan Roth identify compounds that cause the dormant Ube3a gene to be expressed.
Zylka lab graduate student Nathaniel Sowa receives national dissertation award
December 2011 - Nate Sowa, an MD/PhD student who conducted his dissertation research in the lab of Mark Zylka, receives the 2011 Council of Graduate Schools/ProQuest Distinguished Dissertation Award
Philpot and Zylka receive R01 grant funding from the National Institute of Mental Health
National Institute of Mental Health (NIMH) grants Philpot and Zylka an R01 to study drugs that regulate expression of the protein Ube3a.
Joint Zylka and Philpot lab paper is cover article in latest Trends in Neurosciences
The labs of Drs. Ben Philpot and Mark Zylka have collaborated on the paper “Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes,” which was selected as the cover article for the June 2011 issue of Trends in Neurosciences.
Zylka lab postdoc Ian King receives Angelman Syndrome Foundation fellowship
Dr. Ian King is the first recipient of the Dr. Joseph E. Wagstaff Postdoctoral Fellowship Award, a prestigious two-year fellowship award given for studies in preclinical, translational and clinical research areas that investigate all aspects of Angelman syndrome.
Zylka review is cover article for Trends in Molecular Medicine
Dr. Mark Zylka’s review on pain-relieving prospects for adenosine and ectonucleotidases is featured as the cover article in the April 2011 issue of Trends in Molecular Medicine.
UNC Researchers Awarded Prestigious Grant for Research in Autism Spectrum Disorders
UNC Researchers Philpot, Zylka and Roth are awarded a prestigious grant from the Simons Foundation for research in autism spectrum disorders
Molecular bandit keeps pain at bay
Mark Zylka and colleagues have identified an enzyme that blocks chronic pain by robbing a major pain pathway of a key ingredient. The enzyme could prevent lasting pain after surgery.
Mark Zylka receives Transformative R01 Grant
Assistant professor Mark Zylka was awarded one of 42 NIH Roadmap Transformative R01 grants for his project Harnessing Ectonucleotidases to Treat Chronic Pain.
Zylka lab finds that Mrgprd enhances excitability in nociceptive (pain-sensing) neurons
The Journal of Neuroscience publishes findings by the Zylka lab, in collaboration with labs at Caltech and the University of Pittsburgh, that the G protein-coupled receptor called Mrgprd enhances excitability in nociceptive (pain-sensing) neurons.
Video: Zylka and colleagues discover new treatment for pain
Video: Mark Zylka, PhD, and members of his lab, together with colleagues at the University of Helsinki, have discovered a new therapeutic target for pain control, one that appears to be eight times more effective at suppressing pain than morphine.
- Postions Available
-
Contact Dr. Zylka by email for more information.
Graduate Students
- Rotations and permanent positions available. Click here for full description. Students from any graduate program can be readily accommodated.
Postdoctoral
- Electrophysiology. Patch clamp and background in neuroscience preferred. Please email Dr. Zylka your CV.
- Molecular biology / genetics / biochemistry / behavioral. Please email Dr. Zylka your CV.
Mark J. Zylka, PhD
Unsilencing Angelman Syndrome
Angelman syndrome is a severe disorder with symptoms that include speech impairment, intellectual disability and seizures. This lifelong disorder profoundly impacts patients and their families, yet no effective treatment currently exists. It is well established that this disorder is caused by genetic alterations in the maternally-inherited copy of a gene called Ube3a.
In collaboration with Drs. Ben Philpot and Bryan Roth, we found that topoisomerase inhibitors unsilence a dormant but functional copy of Ube3a in mice. We aim to advance our understanding of how these drugs work, with the ultimate goal of developing treatments for this debilitating, lifelong disorder.
For more information, please visit: http://www.cidd.unc.edu/Angelman-Syndrome/.
Molecules and Mechanisms for Pain
Chronic pain is a major medical issue, affecting more Americans than heart disease, diabetes and cancer combined (American Pain Foundation). In our laboratory, we are developing new approaches to treat chronic pain. In addition, we study the neural circuits that transmit pain-producing stimuli using molecular, genetic, electrophysiological and behavioral approaches.
![]() |
| Figure 1. |
Ectonucleotidases in nociceptive circuits.
We recently found that Prostatic Acid Phosphatase (PAP, also know as ACPP) is expressed in nociceptive (pain-sensing) neurons and functions as an ectonucleotidase, converting adenosine monophosphate (AMP) to adenosine. The released adenosine potently suppresses inflammatory pain and neuropathic pain by acting through A1 adenosine receptors.
Our studies suggest it might be possible to treat chronic pain using recombinant PAP protein or small-molecules that mimic the effects of PAP.
Neural circuit-based approaches.
In mammals, pain signals are transmitted from the periphery to the CNS by two neural circuits; the so called peptidergic and non-peptidergic circuits (Fig. 1). Peptidergic neurons contain neuropeptides, like CGRP, while non-peptidergic neurons bind the lectin IB4.
![]() |
We recently found a G protein-coupled receptor (GPCR) called Mrgprd which is expressed in a majority of all non-peptidergic neurons. Mrgprd is not expressed in CGRP+ neurons, nor is it expressed anywhere else in the brain or body.
To identify the tissues that Mrgprd-expressing neurons innervate, we engineered knock-in mice that express a membrane-tethered version of enhanced Green Fluorescent Protein (EGFPf) from the Mrgprd locus (MrgprdΔEGFPf). Surprisingly, we found that Mrgprd-expressing neurons only innervate the epidermis of the skin (Fig. 2). Joints and internal organs were not innervated, suggesting pain signals are transmitted from these tissues by molecularly-distinct circuits.
![]() |
| Figure 3. Dorsal spinal cord. CGRP (red) and Mrgprd (green) axons. PKCγ interneurons (blue) |
In addition to molecular differences, Mrgprd-expressing axons and CGRP+ axons terminate within different zones of the epidermis (Fig. 2). Mrgprd-expressing axons (green) also terminate beneath the red-labeled CGRP lamina in the dorsal spinal cord (Fig. 3). Taken together, these findings suggest peptidergic and non-peptidergic neurons might have unique functions and connectivity.
Although studied for over 20 years, it is still not known why mammals have peptidergic and non-peptidergic circuits, both of which respond to noxious stimuli. Do these two molecularly different circuits have redundant or non-redundant functions in nociception? In our laboratory, we are trying to answer this fundamental question using a variety of approaches. As an example, we are making and studying circuit knockout mice. These mice are specifically missing either peptidergic or non-peptidergic neurons. We are studying the consequences of these ablations using molecular, electrophysiological and behavioral methodologies. We are also using Channelrhodopsin-2 (ChR2), a light-gated ion channel, to better understand how these circuits interface with pain-related regions of the central nervous system.
Techniques used in our lab:
Molecular biology and cell culture
In situ hybridization and immunofluorescence staining
Construction and characterization of knock-in and transgenic mice
Mouse behavioral experiments
Bioinformatics
FACS of neurons
Expression profiling with Affymetrix GeneChip arrays
Calcium imaging and electrophysiology
Recent Publications:
Hurt JK, Zylka MJ. PAPupuncture has localized and long-lasting antinociceptive effects in mouse models of acute and chronic pain. Mol Pain. 2012 Apr 23;8(1):28. [Epub ahead of print]
Huang HS, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, Sciaky N, Dutton JW Jr, Lee HM, Chen X, Jin J, Bridges AS, Zylka MJ, Roth BL, Philpot BD. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature. 2011 Dec 21;481(7380):185-9. doi: 10.1038/nature10726.
Mabb AM, Judson MC, Zylka MJ, Philpot BD. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. Trends Neurosci. 2011 Jun;34(6):293-303. [cover]
Zylka MJ, Sowa NA. NT5E mutations and arterial calcifications. N Engl J Med. 2011 Apr 21;364(16):1579; author reply 1579-80.
Zylka MJ. Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med. 2011 Apr;17(4):188-96. [cover]
Street SE, Zylka MJ. (2011). Emerging roles for ectonucleotidases in pain-sensing neurons. Neuropsychopharmacology 36:358.
Sowa NA, Street SE, Vihko P, Zylka MJ. (2010). Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. J. Neurosci. 30:10282-10293.
Sowa NA, Voss MK, Zylka MJ. (2010) Recombinant ecto-5’-nucleotidase (CD73) has long lasting antinociceptive effects that are dependent on adenosine A1 receptor activation. Molecular Pain. 6:20.
Sowa NA, Taylor-Blake B, Zylka MJ. (2010) Ecto-5’-nucleotidase (CD73) inhibits nociception by hydrolyzing AMP to adenosine in nociceptive circuits. J. Neurosci. 30:2235-2244.
Taylor-Blake B, Zylka MJ. (2010) Prostatic acid phosphatase is expressed in peptidergic and nonpeptidergic nociceptive neurons of mice and rats. PLOS One 5(1):e8674. doi:10.1371/journal.pone.0008674.
Wang H, Zylka MJ. (2009) Mrgprd-expressing polymodal nociceptive neurons innervate most known classes of substantia gelatinosa neurons. J. Neurosci. 29:13202-13209.
Rau KK, McIlwrath SL, Wang H, Lawson JJ, Jankowski MP, Zylka MJ, Anderson DJ, Koerber HR. (2009) Mrgprd enhances excitability in specific populations of cutaneous murine polymodal nociceptors. J Neurosci. 29(26):8612-9.
Larsen RS, Zylka MJ, Scott JE. (2009) A high throughput assay to identify small molecule modulators of prostatic acid phosphatase. Current Chemical Genomics, 3:42-49.
Cavanaugh D, Lee H, Lo L, Shields S, Zylka MJ, Basbaum AI, Anderson DJ. (2009) Distinct subsets of unmyelinated primary sensory fibers mediate behavioral responses to noxious thermal and mechanical stimuli. Proc. Natl. Acad. Sci. USA, 106:9075-9080.
Sowa NA, Vadakkan K, Zylka MJ. (2009) Recombinant mouse PAP has pH-dependent ectonucleotidase activity and acts through A1-adenosine receptors to mediate antinociception. PLOS One, 4(1): e4248. doi:10.1371/journal.pone.0004248.
Zylka MJ, Sowa NA, Taylor-Blake B, Twomey MA, Herrala A, Voikar V, Vihko P. (2008) Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 60:111-22.
Dussor G, Zylka MJ, Anderson DJ, McCleskey EW. (2008) Cutaneous sensory neurons expressing the Mrgprd receptor sense extracellular ATP and are putative nociceptors. J. Neurophysiol. 99:1581-9.
Liu Y, Yang FC, Okuda T, Dong X, Zylka MJ, Chen CL, Anderson DJ, Kuner R, Ma Q. (2008) Mechanisms of compartmentalized expression of Mrg class G protein-coupled sensory receptors. J. Neurosci. 28: 125-32.
Campagnola L, Wang H, Zylka MJ. (2008) Fiber-coupled light-emitting diode for localized photostimulation of neurons expressing channelrhodopsin-2. J Neurosci Methods. 169:27-33.
Liu Q, Vrontou S, Rice FL, Zylka MJ, Dong XD, Anderson DJ. (2007) Molecular genetic visualization of a rare subset of unmyelinated sensory neurons that may detect gentle touch. Nature Neurosci. 10:946-8
Zylka MJ. (2005) Nonpeptidergic circuits feel your pain. Neuron 47:771-772.
Zylka M, Rice FL, Anderson, DJ. (2005) Topographically distinct epidermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd. Neuron 45:17-25.
Zylka MJ, Dong X, Southwell AL, Anderson DJ. (2003) Atypical expansion in mice of the sensory neuron-specific Mrg G protein-coupled receptor family. Proc. Natl. Acad. Sci . USA 100:10043-10048.
Han S-K, Dong X, Hwang J-I, Zylka MJ, Anderson DJ, Simon MI. (2002) Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the G a q/11 pathway. Proc. Natl. Acad. Sci . USA 99:14740-14745.
Dong X, Han S-K, Zylka MJ, Simon MI, Anderson DJ. (2001) A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 106:619-632.




